CA2277273A1 - Antagonistes d'integrine - Google Patents
Antagonistes d'integrine Download PDFInfo
- Publication number
- CA2277273A1 CA2277273A1 CA002277273A CA2277273A CA2277273A1 CA 2277273 A1 CA2277273 A1 CA 2277273A1 CA 002277273 A CA002277273 A CA 002277273A CA 2277273 A CA2277273 A CA 2277273A CA 2277273 A1 CA2277273 A1 CA 2277273A1
- Authority
- CA
- Canada
- Prior art keywords
- beta
- alpha
- antagonists
- vitronectin receptor
- integrin antagonists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3561497P | 1997-01-17 | 1997-01-17 | |
US60/035,614 | 1997-01-17 | ||
GBGB9702788.2A GB9702788D0 (en) | 1997-02-11 | 1997-02-11 | Alpha v beta 3 antagonists |
GB9702788.2 | 1997-02-11 | ||
US6259497P | 1997-10-20 | 1997-10-20 | |
US60/062,594 | 1997-10-20 | ||
GBGB9725996.4A GB9725996D0 (en) | 1997-12-09 | 1997-12-09 | Intergrin antagonists |
GB9725996.4 | 1997-12-09 | ||
PCT/US1998/000617 WO1998031359A1 (fr) | 1997-01-17 | 1998-01-13 | Antagonistes d'integrine |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2277273A1 true CA2277273A1 (fr) | 1998-07-23 |
CA2277273C CA2277273C (fr) | 2008-03-25 |
Family
ID=27451601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002277273A Expired - Fee Related CA2277273C (fr) | 1997-01-17 | 1998-01-13 | Antagonistes d'integrine |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1007026A4 (fr) |
JP (1) | JP2001509176A (fr) |
AU (1) | AU729869B2 (fr) |
CA (1) | CA2277273C (fr) |
WO (1) | WO1998031359A1 (fr) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19629816A1 (de) | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
US6211191B1 (en) | 1997-12-17 | 2001-04-03 | Merck & Co., Inc. | Integrin receptor antagonists |
US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
US6048861A (en) | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
US6066648A (en) | 1997-12-17 | 2000-05-23 | Merck & Co., Inc. | Integrin receptor antagonists |
US6313119B1 (en) | 1998-01-23 | 2001-11-06 | Adventis Pharma Deutschland Gmbh | Sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion |
US6372719B1 (en) | 1998-03-04 | 2002-04-16 | Jay Cunningham | ανβ3 integrin antagonists in combination with chemotherapeutic agents |
GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
IL125336A0 (en) * | 1998-07-14 | 1999-03-12 | Yissum Res Dev Co | Compositions for inhibition and treatment of restinosis |
US7008645B2 (en) | 1998-07-14 | 2006-03-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of inhibiting restenosis using bisphosphonates |
US6984400B2 (en) | 1998-07-14 | 2006-01-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Method of treating restenosis using bisphosphonate nanoparticles |
JP2002521450A (ja) * | 1998-07-29 | 2002-07-16 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体アンタゴニスト |
DE19842415A1 (de) * | 1998-09-16 | 2000-03-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
AU2713600A (en) * | 1998-12-23 | 2000-07-31 | G.D. Searle & Co. | Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia |
CZ20013593A3 (cs) | 1999-04-06 | 2002-03-13 | Sankyo Company, Limited | Alfa-Substituované deriváty karboxylových kyselin |
GB9908355D0 (en) * | 1999-04-12 | 1999-06-09 | Rhone Poulenc Rorer Ltd | Chemical compounds |
GB9910394D0 (en) * | 1999-05-05 | 1999-07-07 | Rhone Poulenc Rorer Ltd | Chemical compounds |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
KR20020021380A (ko) | 1999-06-02 | 2002-03-20 | 폴락 돈나 엘. | 알파 v 인테그린 수용체 길항제 |
AU5379900A (en) * | 1999-06-07 | 2000-12-28 | Shire Biochem Inc. | Thiophene integrin inhibitors |
EP1065208A1 (fr) | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Dérivés substitués de la purine inhibiteurs de l'adhésion cellulaire |
EP1065207A1 (fr) | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Dérivées de la naphthyridine, procédés pour leur preparation, leur utilisation, et compositions pharmaceutique les contenant |
JP2003505416A (ja) * | 1999-07-21 | 2003-02-12 | ワイス | αvβ3インテグリンに対して選択的な二環式拮抗薬 |
EP1209152A4 (fr) | 1999-08-05 | 2003-03-12 | Meiji Seika Kaisha | Derives d'acide omega-amino-alpha-hydroxycarboxylique possedant un antagonisme alpha v beta 3 d'integrine |
US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
EP1332132B1 (fr) | 2000-04-17 | 2007-10-10 | UCB Pharma, S.A. | Derives d'enamine comme molecules d'adhesion cellulaire |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
JP2004503540A (ja) | 2000-06-15 | 2004-02-05 | ファルマシア・コーポレーション | インテグリンアンタゴニストとして有用なジヒドロスチルベンアルカン酸誘導体 |
UY26780A1 (es) | 2000-06-15 | 2002-01-31 | Pharmacia Corp | Cicloalquil avb3 antagonistas |
US6638950B2 (en) | 2000-06-21 | 2003-10-28 | Bristol-Myers Squibb Pharma Company | Piperidine amides as modulators of chemokine receptor activity |
AU2001267753A1 (en) | 2000-07-07 | 2002-01-21 | Celltech R And D Limited | Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists |
JP2004505110A (ja) | 2000-08-02 | 2004-02-19 | セルテック アール アンド ディ リミテッド | 3位置換イソキノリン−1−イル誘導体 |
US6531494B1 (en) | 2001-08-29 | 2003-03-11 | Pharmacia Corporation | Gem-substituted αvβ3 antagonists |
CZ20033119A3 (cs) | 2001-04-24 | 2005-01-12 | Merck Patent Gmbh | Kombinovaná terapie za použití antiangiogenových činidel a TNF alfa |
CN1638790A (zh) | 2002-01-29 | 2005-07-13 | Wyeth公司 | 用于调节连接蛋白半通道的组合物和方法 |
US7365209B2 (en) * | 2003-02-11 | 2008-04-29 | Pharmacopeia, Inc. | Nitrogen heterocycle biaryls for osteoporosis and other diseases |
US10517883B2 (en) | 2003-06-27 | 2019-12-31 | Zuli Holdings Ltd. | Method of treating acute myocardial infarction |
BRPI0414604A (pt) * | 2003-09-23 | 2006-11-07 | Novartis Ag | combinações de um inibiddor do receptor de vegf com outros agentes terapêuticos |
EA016817B1 (ru) | 2006-01-18 | 2012-07-30 | Мерк Патент Гмбх | Специфическая терапия, использующая интегриновые лиганды для лечения рака |
US7589087B2 (en) | 2006-03-31 | 2009-09-15 | Janssen Pharmaceutica, N.V. | Benzoimidazol-2-yl pyridines as modulators of the histamine H4receptor |
CN101460483B (zh) | 2006-03-31 | 2013-05-08 | 詹森药业有限公司 | 作为组胺h4受体调节剂的苯并咪唑-2-基嘧啶和吡嗪 |
KR20090108713A (ko) | 2007-01-18 | 2009-10-16 | 메르크 파텐트 게엠베하 | 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약 |
WO2009079001A1 (fr) | 2007-12-18 | 2009-06-25 | Janssen Pharmaceutica N.V. | Imidazoles bicycliques substitué par hétéroaryle constituant des modulateurs du récepteur de l'histamine h4 |
US9371311B2 (en) | 2008-06-30 | 2016-06-21 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyrimidine derivatives |
KR20120104491A (ko) | 2009-05-25 | 2012-09-21 | 메르크 파텐트 게엠베하 | 암 치료를 위한 실렌기티드의 연속 투여 |
JO3516B1 (ar) | 2013-03-06 | 2020-07-05 | Janssen Pharmaceutica Nv | مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4 |
US9993427B2 (en) | 2013-03-14 | 2018-06-12 | Biorest Ltd. | Liposome formulation and manufacture |
JP6215335B2 (ja) | 2013-09-24 | 2017-10-18 | 富士フイルム株式会社 | 新規な含窒素化合物もしくはその塩またはそれらと金属との錯体 |
RU2016146826A (ru) | 2014-05-30 | 2018-07-04 | Пфайзер Инк. | Производные карбонитрилов как селективные модуляторы андрогенового рецептора |
EP3509590A4 (fr) | 2016-09-07 | 2020-12-02 | Pliant Therapeutics, Inc. | Composés d'acides aminés n-acyle et méthodes d'utilisation |
WO2023275715A1 (fr) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Métabolites de modulateurs sélectifs du récepteur des androgènes |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0673247A4 (fr) * | 1992-12-01 | 1996-05-01 | Merck & Co Inc | Antagonistes des recepteurs du fibrinogene. |
US5563158A (en) * | 1993-12-28 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists |
AU701776B2 (en) * | 1994-05-27 | 1999-02-04 | Merck & Co., Inc. | Compounds for inhibiting osteoclast-mediated bone resorption |
-
1998
- 1998-01-13 CA CA002277273A patent/CA2277273C/fr not_active Expired - Fee Related
- 1998-01-13 AU AU60231/98A patent/AU729869B2/en not_active Ceased
- 1998-01-13 WO PCT/US1998/000617 patent/WO1998031359A1/fr not_active Application Discontinuation
- 1998-01-13 JP JP53447398A patent/JP2001509176A/ja not_active Ceased
- 1998-01-13 EP EP98903466A patent/EP1007026A4/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
EP1007026A4 (fr) | 2002-08-07 |
EP1007026A1 (fr) | 2000-06-14 |
AU6023198A (en) | 1998-08-07 |
CA2277273C (fr) | 2008-03-25 |
JP2001509176A (ja) | 2001-07-10 |
WO1998031359A1 (fr) | 1998-07-23 |
AU729869B2 (en) | 2001-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2277273A1 (fr) | Antagonistes d'integrine | |
CA2315220A1 (fr) | Antagonistes du recepteur de l'integrine | |
DE69720771D1 (en) | Integrin antagonist | |
CA2315189A1 (fr) | Antagonistes du recepteur de l'integrine | |
EP1044001A4 (fr) | Antagonistes du recepteur de l'integrine | |
WO2000072801A3 (fr) | Antagonistes du recepteur de l'alpha v integrine | |
ES2185009T3 (es) | Antagonistas de alfa y beta 3'. | |
AU7793501A (en) | Alpha v integrin receptor antagonists | |
WO2002090325A3 (fr) | Benzazepinones, antagonistes de recepteur d'integrine alpha v | |
YU38300A (sh) | Antagonisti integrinskog receptora | |
YU38200A (sh) | Antagonisti integrinskog receptora |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |